Semaglutid visar starka viktminskningsresultat för vuxna över 65 år

12 maj 2026

Rapporterad av AI

En ny analys av kliniska studier visar att semaglutid, den aktiva substansen i Ozempic och Wegovy, hjälper äldre vuxna med fetma att gå ner avsevärt i vikt och förbättra markörer för hjärthälsa. Resultaten kommer från data om deltagare i åldern 65 år och äldre som fick medicinen en gång i veckan i kombination med livsstilsförändringar.

Forskare ledda av professor Luca Busetto vid Universitetet i Padua granskade resultat från studierna STEP 1, 3, 4, 5, 8 och 9. Analysen fokuserade på 358 vuxna i åldern 65 år eller äldre med fetma men utan diabetes. Av dessa tog 248 personer 2,4 mg semaglutid, medan 110 fick placebo under 68 veckor.

Relaterade artiklar

Realistic illustration contrasting social stigma: neutral for overweight, positive for exercise weight loss, negative for Ozempic users.

Study finds people who use Ozempic-like drugs for weight loss face added stigma

5 maj 2026 Rapporterad av AI Bild genererad av AI Faktagranskad

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Study links Ozempic to lower depression and anxiety risks

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

20 mars 2026 Rapporterad av AI

A real-world study of nearly 8,000 patients by Cleveland Clinic researchers shows that stopping injectable semaglutide or tirzepatide often does not lead to major weight regain. Many participants maintained or continued losing weight by restarting treatment, switching medications, or using lifestyle support. This differs from clinical trials where rapid regain was observed.

Hälsa

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Hälsa

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Hälsa

Gut reset procedure limits weight regain after stopping Ozempic

Trojan horse obesity drug boosts weight loss in mice

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

25 april 2026 Rapporterad av AI

Young Indians are turning to diabetes drugs Ozempic and Mounjaro for rapid weight loss before weddings and job interviews, as experts warn of cosmetic misuse, grey market dangers, and rising lookism. These GLP-1 drugs are meant for obesity and diabetes, not vanity purposes, doctors emphasize.

Study recommends treatment for all children with obesity

A new Karolinska Institutet study finds that children with moderate obesity face higher risks of type 2 diabetes, high blood pressure, and lipid disorders in adulthood, even without apparent risk markers. Researchers urge treatment for all such children.

Testosterone gel plus exercise may limit visceral fat gain in older women recovering from hip fractures

8 maj 2026 Rapporterad av AI Faktagranskad

A University of Connecticut-led clinical trial found that older women recovering from a recent hip fracture who used a topical testosterone gel alongside a structured exercise program did not experience the typical rise in visceral abdominal fat seen during recovery. Researchers followed participants for six months and assessed body composition with imaging scans.

9 april 2026 23:54

Semaglutid visar starka viktminskningsresultat för vuxna över 65 år

Relaterade artiklar

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Study links Ozempic to lower depression and anxiety risks

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Gut reset procedure limits weight regain after stopping Ozempic

Trojan horse obesity drug boosts weight loss in mice

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Study recommends treatment for all children with obesity

Testosterone gel plus exercise may limit visceral fat gain in older women recovering from hip fractures

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Study finds prediabetes remission possible without weight loss

GLP-1 weight loss drugs boost premium chocolate sales

Animal study raises new questions about gut effects of SNAC, an ingredient used in oral semaglutide tablets

New study offers hope for weight loss drugs against alcoholism

Cochrane review finds intermittent fasting no better for weight loss

AI digital twins help manage diabetes and obesity

India today investigation reveals lax drug norms for weight loss injections

Cochrane reviews assess GLP-1 drugs for obesity treatment

Denna webbplats använder cookies